Research Analysts’ Weekly Ratings Updates for Viridian Therapeutics (VRDN)

Viridian Therapeutics (NASDAQ: VRDN) recently received a number of ratings updates from brokerages and research firms:

• 11/6/2025 – Viridian Therapeutics had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $40.00 price target on the stock.
• 11/6/2025 – Viridian Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $41.00 to $45.00. They now have an “outperform” rating on the stock.
• 11/4/2025 – Viridian Therapeutics had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $61.00 price target on the stock.
• 10/21/2025 – Viridian Therapeutics had its price target raised by analysts at Oppenheimer Holdings, Inc. from $32.00 to $36.00. They now have an “outperform” rating on the stock.
• 10/8/2025 – Viridian Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Viridian Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc acquired 454,545 shares of Viridian Therapeutics stock in a transaction dated Thursday, October 23rd. The shares were purchased at an average price of $22.00 per share, for a total transaction of $9,999,990.00. Following the completion of the transaction, the director directly owned 3,914,458 shares in the company, valued at approximately $86,118,076. This represents a 13.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.58% of the company’s stock.

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.